Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says

In a letter seen by MarketWatch, the activist fund blamed the sharp drop in Novavax’s sales on the U.S. vaccine-maker’s management, as it called for an overhaul of the company’s marketing strategy to target people who do not want to take mRNA vaccines.#marketwatch #novavax

Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news